Cost-effectiveness of disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial carcinoma in China.

Aidixi (disitamab vedotin) - Pfizer, RemeGen

Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42577582

Haoyun Chen; Huanjun Huang; Weicheng Lei; Weijia He; Weiting Liang; Ya Guo; Zhijun Guo; Zhuojia Chen

Aug 12, 2026